ADMA Biologics 과거 순이익 실적
과거 기준 점검 3/6
ADMA Biologics은 연평균 70.3%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 수입이 33.8% 증가했습니다. 매출은 연평균 40.4%의 비율로 증가했습니다. ADMA Biologics의 자기자본이익률은 42.4%이고 순이익률은 32.4%입니다.
핵심 정보
70.25%
순이익 성장률
72.60%
주당순이익(EPS) 성장률
| Biotechs 산업 성장률 | 17.04% |
| 매출 성장률 | 40.45% |
| 자기자본이익률 | 42.36% |
| 순이익률 | 32.43% |
| 최근 순이익 업데이트 | 31 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • May 08
ADMA: Long Term Revenue Outlook And Buybacks Will Support Future Upside
Analysts have trimmed their price targets on ADMA Biologics by roughly one third to about $18.33, citing updated assumptions around growth, profitability, and future P/E multiples following recent initiation, target cuts, and a downgrade. Analyst Commentary Recent Street research around ADMA Biologics reflects both optimism about the company’s setup and fresh caution around execution and valuation, which is feeding directly into the trimmed price targets.
내러티브 업데이트 • Apr 20
ADMA: Long Term Guidance And Buybacks Will Counter Post Short Report Caution
Analysts have trimmed their view on ADMA Biologics, cutting the consensus price target by $6 to reflect increased caution following recent downgrades and questions raised after a short report, even as long term profitability assumptions and P/E expectations remain broadly steady. Analyst Commentary Recent research updates point to a more cautious tone around ADMA Biologics, with bearish analysts trimming price targets and shifting ratings to reflect higher perceived risk following the short report and subsequent uncertainty.내러티브 업데이트 • Apr 05
ADMA: Long Term Guidance And Buybacks Will Support Post Short Report Upside
Analysts have nudged their price target for ADMA Biologics to $17.00, reflecting updated assumptions on revenue growth, profit margins, discount rate and future P/E following recent downgrades and reduced clarity cited in Street research. Analyst Commentary Recent Street research has taken a more cautious stance on ADMA Biologics, with bearish analysts reassessing their views after a short report introduced fresh uncertainty around the story.Seeking Alpha • Mar 29
ADMA Biologics: Differentiated Plasma Approach With Asymmetric Upside Potential (Rating Upgrade)
Summary ADMA Biologics markets three FDA-approved immune globulin products, with ASCENIV serving as its main growth driver. My bull thesis centers on ADMA’s differentiated high-titer plasma sourcing and potential for gaining further market share in a large IG market. ADMA’s valuation also appears substantially cheaper relative to its peers, despite having positive cash flows and promising revenue growth. Thus, ADMA continues to project improving adjusted EBITDA margins. So, I remain optimistic, despite the recent negative stock price performance. Read the full article on Seeking Alpha내러티브 업데이트 • Mar 22
ADMA: Long Term Revenue Guidance And Buybacks Will Support Bullish Outlook
Analysts are maintaining their $17.00 price target on ADMA Biologics, as only minor adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions do not materially change their view of the stock's valuation. What's in the News ADMA completed a share repurchase program announced on May 7, 2025, buying back a total of 1,919,070 shares, or 0.8% of shares, for US$31.92 million, including 590,422 shares, or 0.25% of shares, for US$8.91 million between October 1, 2025 and December 31, 2025 (Key Developments).
내러티브 업데이트 • Mar 08
ADMA: Multiyear Revenue Guidance And Share Buybacks Will Support Future Upside
Analysts have modestly revised their price target on ADMA Biologics to $30.00, reflecting updated assumptions around slightly lower revenue growth, a higher profit margin, and a somewhat lower future P/E multiple. The fair value estimate remains at $30.00.내러티브 업데이트 • Feb 21
ADMA: Long-Term Revenue Outlook And Margins Will Support Current Fair Value
Analysts have modestly fine tuned their price target on ADMA Biologics to $17.00, citing slightly higher modeled revenue growth and profit margins, along with a marginally lower future P/E assumption, as key drivers of their updated view. What's in the News ADMA Biologics issued earnings guidance for 2027, expecting total revenue of approximately $775m.내러티브 업데이트 • Feb 07
ADMA: Long Term Revenue Guidance Will Support Future Upside Potential
Analysts have maintained their fair value target for ADMA Biologics at $30.00. They have made small adjustments to inputs such as discount rate, revenue growth, profit margin, and future P/E to fine-tune their underlying assumptions rather than alter the headline valuation.내러티브 업데이트 • Jan 24
ADMA: Raised Revenue Guidance And Margin Gains Will Offset Higher Discount Rate
Analysts have raised their price target on ADMA Biologics to US$17.00, reflecting updated views on slightly higher projected revenue growth, a stronger profit margin profile, a modest adjustment to the discount rate, and a lower assumed future P/E multiple. What's in the News Raised preliminary unaudited earnings guidance for fiscal 2025, with total revenue now expected between approximately US$510 million and US$511 million (Corporate Guidance: Raised).내러티브 업데이트 • Jan 10
ADMA: Raised Long Term Revenue Guidance And Buybacks Will Support Upside
Analysts have trimmed their price target on ADMA Biologics from US$35.00 to US$30.00, pointing to updated assumptions around a modestly higher discount rate, slightly lower revenue growth expectations, a higher projected profit margin, and a lower future P/E multiple. What's in the News ADMA Biologics completed a share repurchase program announced on May 7, 2025, buying back a total of 1,328,648 shares, or 0.56% of shares, for US$23.01 million, including 512,411 shares, or 0.21%, for US$8.03 million from July 1 to September 30, 2025 (Key Developments).내러티브 업데이트 • Dec 25
ADMA: Higher Discount Rate Will Outweigh Stronger Revenue Outlook
Analysts have trimmed their price target on ADMA Biologics from 19.24 dollars to 17.00 dollars, citing the need for a slightly higher discount rate and modestly lower long term margin assumptions, despite a somewhat stronger revenue growth outlook and more conservative future valuation multiples. What's in the News Raised revenue guidance for fiscal 2025 to at least $510 million, up from more than $500 million previously (Company guidance) Increased fiscal 2026 revenue outlook to at least $630 million, compared with prior guidance of $625 million or more (Company guidance) Introduced long term guidance targeting total annual revenue of $1.1 billion or more by 2029, with expectations for earnings growth above current margin levels (Company guidance) Completed a share repurchase of 1,328,648 shares, or 0.56 percent of outstanding shares, for $23.01 million under the buyback program announced on May 7, 2025, including 512,411 shares repurchased in the most recent tranche (Buyback update) Valuation Changes Fair Value Estimate trimmed from $19.24 to $17.00, a modest downward revision of roughly 12 percent.내러티브 업데이트 • Dec 11
ADMA: Share Repurchases And Long Term Revenue Outlook Will Drive Future Upside
Narrative Update on ADMA Biologics Analysts have maintained their price target for ADMA Biologics at 27.25 dollars, reflecting largely unchanged assumptions around discount rate, revenue growth, profit margins, and future valuation multiples. This signals continued confidence in the company’s long term earnings trajectory and risk profile.분석 기사 • Dec 02
ADMA Biologics, Inc. (NASDAQ:ADMA) Looks Just Right With A 25% Price Jump
ADMA Biologics, Inc. ( NASDAQ:ADMA ) shares have had a really impressive month, gaining 25% after a shaky period...내러티브 업데이트 • Nov 27
ADMA: Share Repurchases And Rising Earnings Guidance Will Support Future Upside
Analysts have maintained their price target for ADMA Biologics at $27.25 per share, citing stable financial projections and consistent optimism regarding the company's growth prospects. What's in the News From July 1, 2025 to September 30, 2025, ADMA Biologics repurchased 512,411 shares, completing a total buyback of 1,328,648 shares for $23.01 million as announced in May 2025 (Key Developments).내러티브 업데이트 • Nov 12
ADMA: Buyback Activity And Margin Expansion Will Drive Robust Results
Analysts have increased their price target for ADMA Biologics to $27.25. They cite expectations for stronger revenue growth and higher profit margins, balanced against a slightly higher discount rate and declining future price-to-earnings multiples.내러티브 업데이트 • Oct 29
Share Repurchase And Higher Margins Will Drive Future Upside Potential
Analysts have slightly lowered their price target for ADMA Biologics from $27.81 to $27.25. They cited modest adjustments in financial assumptions, including revenue growth and profit margins.내러티브 업데이트 • Oct 14
Optimized Yield Process And Expanding Capacity Will Build Lasting Momentum
Analysts have lowered their price target for ADMA Biologics from $29.06 to $27.81, primarily because of slight adjustments in fair value and future price-to-earnings estimates. Revenue growth and profit margin projections remain largely unchanged.Seeking Alpha • Mar 21
ADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future Potential
Summary ADMA Biologics shows robust revenue growth, driven by its innovative IVIG product, ASCENIV, which targets primary humoral immunodeficiency and includes RSV antibodies. Q4 earnings reveal a 59% year-over-year revenue increase, with strong gross profit margins and minimal R&D expenses, highlighting ADMA's efficient operations. Financial health is solid with $103.147 million in cash and manageable liabilities, supporting long-term growth and investment potential. Despite some overvaluation, ADMA's differentiated products, vertical integration, and strong patent portfolio justify a "buy" rating, with future R&D progress being critical. Read the full article on Seeking Alpha분석 기사 • Feb 26
Revenues Not Telling The Story For ADMA Biologics, Inc. (NASDAQ:ADMA)
With a median price-to-sales (or "P/S") ratio of close to 10.4x in the Biotechs industry in the United States, you...Seeking Alpha • Feb 06
ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add
Summary ADMA Biologics specializes in primary immune deficiencies with Asceniv, a high-margin, unique product that outperforms competitors and has significant growth potential in the U.S. market. Asceniv's high-titer plasma offers superior protection with minimal side effects, positioning it as a leading second-line treatment for severe PI patients. ADMA's strategic plasma collection expansion and patented methods ensure a reliable supply, supporting future growth and high-margin revenue projections exceeding $1 billion by 2030. With minimal risks and a strong competitive advantage, ADMA Biologics presents a compelling long-term investment opportunity, especially following the recent stock pullback. Read the full article on Seeking Alpha분석 기사 • Dec 31
Does ADMA Biologics (NASDAQ:ADMA) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Seeking Alpha • Dec 02
ADMA Biologics: Capitalizing On A $20 Billion IG Market With ASCENIV
Summary ADMA Biologics is a rapidly growing player in plasma-derived therapies, with a 78% YoY revenue increase and a 1,300% YoY net income boost. The company’s key product, ASCENIV, is expected to drive significant revenue growth and improve margins, supported by a completed pediatric trial and upcoming sBLA submission. Past legal controversies about an auditor's resignation caused temporary investor concerns, but now appear resolved with KPMG’s appointment as ADMA’s new accounting firm. Thus, I think legal risks have subsided. Now, looking forward, SG-001 could also become a future growth driver if successfully researched and commercialized. Despite a premium valuation, I believe ADMA's growth potential in the $20 billion IG market by 2030 justifies a "Buy" rating for long-term investors. Read the full article on Seeking Alpha분석 기사 • Nov 26
Subdued Growth No Barrier To ADMA Biologics, Inc. (NASDAQ:ADMA) With Shares Advancing 36%
ADMA Biologics, Inc. ( NASDAQ:ADMA ) shareholders would be excited to see that the share price has had a great month...새로운 내러티브 • Nov 20
Valuation analysis
11-NOV-2024Actual company guidance: 2024: 415 MUSD revenue (S24) and net income 120 MUSD (E24), 2025: 465 MUSD (S25), 165 MUSD net income (E25)Market cap of 5.35 BUSD (P) at 22.62/share: P/S24 = 12.9,분석 기사 • Oct 09
ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues
ADMA Biologics, Inc. ( NASDAQ:ADMA ) shares have continued their recent momentum with a 27% gain in the last month...Seeking Alpha • Oct 02
ADMA Biologics: Riding High On ASCENIV's Success
Summary ADMA Biologics reported $107.2 million in Q2 2024 revenue, a 78% year-over-year increase, with ASCENIV being the primary growth driver. ASCENIV now contributes over 50% of ADMA's total revenue, with significant market potential in treating refractory immunodeficient patients. ASCENIV's unique formulation and potential market penetration could drive peak annual sales over $1 billion, though technological advancements and existing competition pose risks. Despite high valuation, ADMA Biologics' diversified revenue streams and solid financial health justify maintaining a "buy" rating with a dollar-cost averaging strategy. Read the full article on Seeking Alpha분석 기사 • Sep 06
ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price
Key Insights The projected fair value for ADMA Biologics is US$26.20 based on 2 Stage Free Cash Flow to Equity Current...
새로운 내러티브 • Sep 03
ASCENIV Drives Revenue Surge, Shaping A Bright Future For The Biotech Leader
ADMA Biologics showcases rapid revenue growth and operational efficiency, with ASCENIV's success significantly impacting future growth.분석 기사 • Aug 16
ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality
ADMA Biologics, Inc. ( NASDAQ:ADMA ) recently posted some strong earnings, and the market responded positively. We have...Seeking Alpha • Jul 27
ADMA Biologics: A Compelling GARP Stock For Biotech Investors
Summary ADMA Biologics focuses on developing and commercializing plasma-derived products, primarily targeting immune-compromised patients. Revenue streams come from FDA-approved products, immunotechnology, and CDMO services, with a promising US immunoglobulin market. The company’s IP portfolio includes three FDA-approved drugs: Asceniv, Bivigam, and Nabi-HB. ADMA's revenue growth is driven by the expanding US immunoglobulin market, projected to exceed $20 billion by 2030. Despite a high valuation premium, I deem ADMA a "buy" for GARP biotech investors due to its revenue growth projections. Read the full article on Seeking Alpha분석 기사 • Jul 24
ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, ADMA Biologics, Inc. ( NASDAQ:ADMA ) shares have been powering on, with a gain of 25% in...분석 기사 • Jul 17
Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...분석 기사 • May 30
Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, ADMA Biologics fair value estimate is US$16.37 Current share...분석 기사 • May 13
ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next
A week ago, ADMA Biologics, Inc. ( NASDAQ:ADMA ) came out with a strong set of quarterly numbers that could potentially...Seeking Alpha • May 12
Giving ADMA Biologics A Well-Deserved 'Booyah'
Summary ADMA Biologics reported stellar Q1 results after the bell on Thursday, May 9th, and the stock shot forward by 27% in trading on Friday. The company seems to be executing on all cylinders, and management ratcheted up forward guidance for both FY2024 and FY2025. Can the shares continue to rally after this 'Booyah' quarter? An updated analysis around ADMA Biologics follows in the paragraphs below. Read the full article on Seeking Alpha분석 기사 • May 08
ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares
You may think that with a price-to-sales (or "P/S") ratio of 6.2x ADMA Biologics, Inc. ( NASDAQ:ADMA ) is definitely a...분석 기사 • Apr 04
Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Apr 03
Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Summary ADMA Biologics' stock has seen a significant rally, fueled by growth in plasma-derived biologics and improved financial health. Recent earnings highlight revenue growth, operational efficiencies, and a shift towards profitability, with notable progress in reducing operating expenses. Future growth is anticipated from Asceniv's market penetration and a promising pipeline, including a potential treatment for strep pneumonia. Despite a substantial stock price increase, ADMA's solid fundamentals and strategic market position justify an upgrade to a "Buy" recommendation. Investors are advised to approach ADMA with caution, considering its speculative nature, while also acknowledging its potential for high returns within a diversified portfolio. Read the full article on Seeking AlphaSeeking Alpha • Jan 19
ADMA Biologics: On A Roll Entering 2024
Summary ADMA Biologics enters 2024 on quite a roll and the stock should continue to do well going forward. The company has recently completed the build of its plasma collection network, turned the corner on profitability, and redid its credit facility in a positive way. Why momentum for ADMA Biologics should continue in 2024 is highlighted below. Read the full article on Seeking Alpha분석 기사 • Jan 09
Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?
Key Insights The projected fair value for ADMA Biologics is US$9.56 based on 2 Stage Free Cash Flow to Equity Current...분석 기사 • Jan 09
ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, ADMA Biologics, Inc. ( NASDAQ:ADMA ) shares have been powering on, with a gain of 30% in...분석 기사 • Oct 25
We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...매출 및 비용 세부 내역
매출 및 비용 세부 내역
ADMA Biologics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 510 | 165 | 99 | 7 |
| 31 Dec 25 | 510 | 147 | 96 | 5 |
| 30 Sep 25 | 489 | 209 | 96 | 4 |
| 30 Jun 25 | 474 | 209 | 93 | 3 |
| 31 Mar 25 | 459 | 207 | 87 | 2 |
| 31 Dec 24 | 426 | 198 | 78 | 2 |
| 30 Sep 24 | 383 | 68 | 69 | 2 |
| 30 Jun 24 | 330 | 35 | 65 | 2 |
| 31 Mar 24 | 283 | -4 | 63 | 3 |
| 31 Dec 23 | 258 | -28 | 63 | 3 |
| 30 Sep 23 | 234 | -23 | 66 | 4 |
| 30 Jun 23 | 208 | -40 | 69 | 4 |
| 31 Mar 23 | 182 | -48 | 69 | 4 |
| 31 Dec 22 | 154 | -66 | 70 | 4 |
| 30 Sep 22 | 130 | -70 | 68 | 2 |
| 30 Jun 22 | 110 | -73 | 64 | 2 |
| 31 Mar 22 | 94 | -78 | 61 | 2 |
| 31 Dec 21 | 81 | -72 | 55 | 3 |
| 30 Sep 21 | 69 | -74 | 49 | 4 |
| 30 Jun 21 | 58 | -74 | 46 | 5 |
| 31 Mar 21 | 48 | -75 | 43 | 5 |
| 31 Dec 20 | 42 | -76 | 39 | 6 |
| 30 Sep 20 | 40 | -67 | 36 | 5 |
| 30 Jun 20 | 37 | -61 | 33 | 4 |
| 31 Mar 20 | 36 | -54 | 30 | 3 |
| 31 Dec 19 | 29 | -48 | 28 | 2 |
| 30 Sep 19 | 21 | -56 | 29 | 3 |
| 30 Jun 19 | 18 | -59 | 29 | 3 |
| 31 Mar 19 | 16 | -61 | 29 | 4 |
| 31 Dec 18 | 17 | -66 | 30 | 4 |
| 30 Sep 18 | 18 | -61 | 30 | 4 |
| 30 Jun 18 | 18 | -61 | 28 | 5 |
| 31 Mar 18 | 17 | -55 | 23 | 5 |
| 31 Dec 17 | 16 | -44 | 21 | 6 |
| 30 Sep 17 | 14 | -35 | 18 | 5 |
| 30 Jun 17 | 12 | -24 | 16 | 5 |
| 31 Mar 17 | 11 | -21 | 17 | 7 |
| 31 Dec 16 | 11 | -20 | 14 | 8 |
| 30 Sep 16 | 10 | -20 | 12 | 9 |
| 30 Jun 16 | 9 | -20 | 12 | 10 |
| 31 Mar 16 | 8 | -19 | 12 | 8 |
| 31 Dec 15 | 7 | -18 | 11 | 7 |
| 30 Sep 15 | 6 | -17 | 11 | 7 |
| 30 Jun 15 | 6 | -15 | 9 | 6 |
양질의 수익: ADMA는 고품질 수익을 보유하고 있습니다.
이익 마진 증가: ADMA의 현재 순 이익률 (32.4%)은 지난해 (45%)보다 낮습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: ADMA는 지난 5년 동안 흑자전환하며 연평균 70.3%의 수익 성장을 기록했습니다.
성장 가속화: ADMA은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.
수익 대 산업: ADMA은 지난 1년 동안 수익이 감소(-20%)하여 Biotechs 업계 평균(43%)과 비교하기 어렵습니다.
자기자본이익률
높은 ROE: ADMA의 자본 수익률(42.4%)은 뛰어남으로 평가됩니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/24 06:34 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
ADMA Biologics, Inc.는 11명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Gary Nachman | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Prem Chulaki | CrispIdea |